全文获取类型
收费全文 | 13210篇 |
免费 | 1420篇 |
国内免费 | 732篇 |
专业分类
儿科学 | 60篇 |
妇产科学 | 17篇 |
基础医学 | 952篇 |
口腔科学 | 6篇 |
临床医学 | 902篇 |
内科学 | 4627篇 |
皮肤病学 | 2篇 |
神经病学 | 8篇 |
特种医学 | 911篇 |
外国民族医学 | 29篇 |
外科学 | 2011篇 |
综合类 | 2136篇 |
现状与发展 | 9篇 |
预防医学 | 190篇 |
眼科学 | 2篇 |
药学 | 591篇 |
1篇 | |
中国医学 | 185篇 |
肿瘤学 | 2723篇 |
出版年
2024年 | 33篇 |
2023年 | 311篇 |
2022年 | 313篇 |
2021年 | 676篇 |
2020年 | 593篇 |
2019年 | 569篇 |
2018年 | 462篇 |
2017年 | 649篇 |
2016年 | 623篇 |
2015年 | 712篇 |
2014年 | 858篇 |
2013年 | 813篇 |
2012年 | 725篇 |
2011年 | 860篇 |
2010年 | 708篇 |
2009年 | 651篇 |
2008年 | 651篇 |
2007年 | 704篇 |
2006年 | 644篇 |
2005年 | 616篇 |
2004年 | 477篇 |
2003年 | 416篇 |
2002年 | 363篇 |
2001年 | 382篇 |
2000年 | 297篇 |
1999年 | 214篇 |
1998年 | 218篇 |
1997年 | 162篇 |
1996年 | 121篇 |
1995年 | 91篇 |
1994年 | 102篇 |
1993年 | 81篇 |
1992年 | 70篇 |
1991年 | 44篇 |
1990年 | 42篇 |
1989年 | 21篇 |
1988年 | 23篇 |
1987年 | 15篇 |
1986年 | 13篇 |
1985年 | 8篇 |
1984年 | 7篇 |
1983年 | 4篇 |
1982年 | 2篇 |
1981年 | 3篇 |
1980年 | 3篇 |
1979年 | 3篇 |
1978年 | 2篇 |
1976年 | 3篇 |
1975年 | 2篇 |
1973年 | 2篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Tumor tissue is composed of tumor cells and tumor stroma. Tumor stroma contains various immune cells and non-immune stromal cells, forming a complex tumor microenvironment which plays pivotal roles in regulating tumor growth. Recent successes in immunotherapies against tumors, including immune checkpoint inhibitors, have further raised interests in the immune microenvironment of liver carcinoma. The immune microenvironment of tumors is formed because of interactions among tumor cells, immune cells and non-immune stromal cells, including fibroblasts and endothelial cells. Different patterns of immune microenvironment are observed among different tumor subtypes, and their clinicopathological significance and intertumor/intratumor heterogeneity are being intensively studied. Here, we review the immune microenvironment of hepatocellular carcinoma, intrahepatic cholangiocarcinoma and liver metastasis of colorectal adenocarcinoma, focusing on its histopathological appearance, clinicopathological significance, and relationship with histological and molecular classifications. Understanding the comprehensive histopathological picture of a tumor immune microenvironment, in addition to molecular and genetic approaches, will further potentiate the effort for precision medicine in the era of tumor-targeting immunotherapy. 相似文献
2.
《Journal of vascular and interventional radiology : JVIR》2022,33(6):660-667
PurposeTo investigate the safety and efficacy of an aqueous polyethylene glycol-based liquid embolic agent, Embrace Hydrogel Embolic System (HES), in the treatment of benign and malignant hypervascular tumors.Materials and MethodsA prospective, single-arm, multicenter study included 8 patients, 5 males and 3 females, with a median age of 58.5 years (30–85 years), who underwent embolization in 8 tumors between October 2019 and May 2020. Technical success was defined as successful delivery of HES to the index vessel, with disappearance of >90% of the targeted vascular enhancement or, for portal vein embolization, occlusion of the portal branches to the liver segments for future resection. The volume of HES administered, ease of use (5 point Likert scale), administration time, and adverse events (AEs) were recorded. Evaluation was performed at 7, 30, and 90 days via clinical assessment and blood testing, and follow-up imaging was performed at 30 days.ResultsEight patients were enrolled, and 10 embolizations were performed in 8 lesions. Tumors included hepatocellular carcinoma (n = 4), renal angiomyolipoma (n = 3), and intrahepatic cholangiocarcinoma (n = 1). Technical success was 100%, and the average ease of use was 3.3 ± 1.0 SD. The HES delivery time was 1–28 minutes (median, 16.5 minutes), and the HES volume injected was 0.4–4.0 mL (median, 1.3 mL). All patients reached 30-day follow-up with imaging, and 6 patients reached 90-day follow-up. There were 3 serious AEs in 2 patients that were unrelated to the embolic agent.ConclusionHES resulted in a 100% embolization technical success rate. The product ease of use was acceptable, and no target vessel recanalization was noted on follow-up imaging at 30 days. 相似文献
3.
《Journal of vascular and interventional radiology : JVIR》2020,31(1):25-34
PurposeTo investigate the safety of yttrium-90 radioembolization in combination with checkpoint inhibitor immunotherapy for the treatment of hepatocellular carcinoma (HCC).Materials and MethodsThis single-center retrospective study included 26 consecutive patients with HCC who received checkpoint inhibitor immunotherapy within 90 days of radioembolization from April 2015 to May 2018. Patients had preserved liver function (Child-Pugh scores A–B7) and either advanced HCC due to macrovascular invasion or limited extrahepatic disease (21 patients) or aggressive intermediate stage HCC that resulted in earlier incorporation of systemic immunotherapy (5 patients). Clinical documentation, laboratory results, and imaging results at 1- and 3-month follow-up intervals were reviewed to assess treatment-related adverse events and treatment responses.ResultsThe median follow-up period after radioembolization was 7.8 months (95% confidence interval [CI], 5.6–11.8). There were no early (30-day) mortality or grades 3/4 hepatobiliary or immunotherapy-related toxicities. Delayed grades 3/4 hepatobiliary toxicities (1–3 months) occurred in 2 patients in the setting of HCC disease progression. One patient developed pneumonitis. The median overall survival from first immunotherapy was 17.2 months (95% CI, 10.9–23.4). The median overall survival from first radioembolization was 16.5 months (95% CI, 6.6–26.4). From first radioembolization, time to tumor progression was 5.7 months (95% CI, 4.2–7.2), and progression-free survival was 5.7 months (95% CI, 4.3–7.1).ConclusionsRadioembolization combined with checkpoint inhibitor immunotherapy in cases of HCC appears to be safe and causes limited treatment-related toxicity. Future prospective studies are needed to identify the optimal combination treatment protocols and evaluate the efficacy of combination therapy. 相似文献
4.
5.
6.
随着腹腔镜肝切除技术的发展与推广,腹腔镜肝切除中的一些难点,如术中出血的控制、解剖性肝切除、巨大肝癌切除、腹腔镜下联合肝脏分割与门静脉支结扎的二步肝切除术(ALPPS)等方面均基本解决。术中超声与荧光染色技术也得到普及。本文就上述问题做一概述,并对腹腔镜肝切除未来发展提出思路,以进一步推动我国腹腔镜肝切除的技术进步。 相似文献
7.
8.
Kun Ma Jiayun Liu Youjin Wang Yubin Zhong Zhenfeng Wu Ruiying Fan Shanfeng Guo 《Journal of gastrointestinal oncology.》2020,11(6):1350
BackgroundOur study aims to investigate changes in cell-free DNA (cfDNA) concentration and integrity in primary hepatocellular carcinoma (PHC) patients before and after transcatheter arterial chemoembolization (TACE) treatment and their influence on the evaluation of prognosis of the disease.MethodsA total of 84 PHC patients admitted to the Affiliated Hospital of Nanjing University of Chinese Medicine from December 2016 to December 2017 were included as the study group, while 55 healthy people served as the control group. Plasma cfDNA concentration and integrity were determined using qRT-PCR. The correlation between cfDNA concentration/integrity and clinical characteristics of PHC patients were analyzed. A ROC curve was used to investigate the sensitivity and specificity of cfDNA as detection indices. Univariate and multivariate analyses were used to analyze factors affecting recurrence in PHC patients and compare recurrence-free survival (RFS) of PHC patients with high cfDNA expression and low cfDNA expression.ResultsPlasma cfDNA concentration and integrity were significantly higher in PHC patients before TACE treatment than in healthy people and significantly lower after treatment than before (P<0.05). The cfDNA concentration was significantly correlated with tumor size, lymph node metastasis, TNM stage, and BCLC stage, while cfDNA integrity was significantly correlated with tumor size, TNM stage, and BCLC stage (P<0.05). ROC results showed that the area under the curve (AUC) value of cfDNA concentration was the largest, with an optimal cut-off of 10.51 ng/mL. Multivariate regression analysis for COX showed that the TNM stage, cfDNA concentration, and AFP were independent risk factors that affected PHC patients’ survival.ConclusionsPlasma cfDNA concentration in PHC patients is more sensitive and specific than any other tumor marker. It is an independent risk factor for PHC patients treated with TACE. Therefore, it is hypothesized cfDNA is a potential biomarker for prognostic evaluation of PHC patients treated with TACE. 相似文献
9.
10.